Cargando…
The impact of an educational and information systems initiative on somatic BRCA testing rates in patients with high grade serous tubo-ovarian cancer in Western Australia
OBJECTIVE: Poly-ADP ribose polymerase inhibitors (PARPi) have expanded the management armamentarium against high grade serous tubo-ovarian cancer (HGSOC) in patients with germline and somatic BRCA pathogenic variants (PVs). Germline testing has been available in Western Australia (WA) since July 201...
Autores principales: | Fantoni, Andrew, Meniawy, Tarek, Cohen, Paul A., McMullen, Michelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372359/ https://www.ncbi.nlm.nih.gov/pubmed/37520785 http://dx.doi.org/10.1016/j.gore.2023.101246 |
Ejemplares similares
-
Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma
por: Gornjec, Andreja, et al.
Publicado: (2019) -
Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
por: Saner, Flurina A. M., et al.
Publicado: (2023) -
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020) -
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023) -
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
por: Hollis, Robert L., et al.
Publicado: (2022)